Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.61 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913040 | 1.00 | SIRT2 (0.61) | SIRT2NMBRKLK5CTSSCTSL | |
| SCHEMBL18221655 | 0.93 | SIRT2 (0.56) | SIRT2NMBRKLK5 | |
| SCHEMBL29401183 | 0.92 | SIRT2 (0.53) | SIRT2NMBR | |
| SCHEMBL9959535 | 0.92 | SIRT2 (0.53) | SIRT2NMBR | |
| SCHEMBL5349888 | 0.92 | SIRT2 (0.53) | SIRT2NMBR | |
| SCHEMBL5361692 | 0.90 | SIRT2 (0.53) | SIRT2NMBRKLK7 | |
| SCHEMBL29606071 | 0.88 | SIRT2 (0.50) | SIRT2NMBRCTSSCTSLCTSB | |
| SCHEMBL5353860 | 0.88 | SIRT2 (0.50) | SIRT2NMBRCTSSCTSLCTSB | |
| SCHEMBL5353862 | 0.88 | SIRT2 (0.54) | SIRT2NMBRCTSSCTSLCTSB | |
| SCHEMBL29918001 | 0.88 | SIRT2 (0.50) | SIRT2NMBRKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149658-A1 | Novel Histidine Derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149658-A1 | Novel Histidine Derivatives | HRH4, HNMT, HRH3 | SIRT2 1706/4885NMBR 396/4885KLK5 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.